TITLE

Test performance of faecal occult blood testing for the detection of bowel cancer in people with chronic kidney disease (DETECT) protocol

AUTHOR(S)
Wong, Germaine; Howard, Kirsten; Chapman, Jeremy R.; Tong, Allison; Bourke, Michael J.; Hayen, Andrew; Macaskill, Petra; Hope, Richard L.; Williams, Narelle; Kieu, Anh; Allen, Richard; Chadban, Steven; Pollock, Carol; Webster, Angela; Roger, Simon D.; Craig, Jonathan C.
PUB. DATE
January 2011
SOURCE
BMC Public Health;2011, Vol. 11 Issue 1, p516
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Cancer is a major cause of mortality and morbidity in patients with chronic kidney disease (CKD). In patients without kidney disease, screening is a major strategy for reducing the risk of cancer and improving the health outcomes for those who developed cancers by detecting treatable cancers at an early stage. Among those with CKD, the effectiveness, the efficacy and patients' preferences for cancer screening are unknown. Methods/Design: This work describes the protocol for the DETECT study examining the effectiveness, efficiency and patient's perspectives of colorectal cancer screening using immunochemical faecal occult blood testing (iFOBT) for people with CKD. The aims of the DETECT study are 1) to determine the test performance characteristics of iFOBT screening in individuals with CKD, 2) to estimate the incremental costs and health benefits of iFOBT screening in CKD compared to no screening and 3) to elicit patients' perspective for colorectal cancer screening in the CKD population. Three different study designs will be used to explore the uncertainties surrounding colorectal cancer screening in CKD. A diagnostic test accuracy study of iFOBT screening will be conducted across all stages of CKD in patients ages 35-70. Using individually collected direct healthcare costs and outcomes from the diagnostic test accuracy study, cost-utility and cost-effective analyses will be performed to estimate the costs and health benefits of iFOBT screening in CKD. Qualitative in-depth interviews will be undertaken in a subset of participants from the diagnostic test accuracy study to investigate the perspectives, experiences, attitudes and beliefs about colorectal cancer screening among individuals with CKD. Discussion: The DETECT study will target the three major unknowns about early cancer detection in CKD. Findings from our study will provide accurate and definitive estimates of screening efficacy and efficiency for colorectal cancer, and will allow better service planning and budgeting for early cancer detection in this at-risk population. The DETECT study is also registered with the Australia New Zealand Clinical Trials Registry ACTRN12611000538943
ACCESSION #
63971489

 

Related Articles

  • Diagnosis of colorectal cancer from tissue sample passed per rectum. Wilson, Iain; Pancholi, Alok; Chan, Shirley // International Journal of Colorectal Disease;Aug2014, Vol. 29 Issue 8, p1021 

    A letter to the editor is presented that discusses the diagnosis of colorectal cancer from tissue sample passed per rectum.

  • Evaluating Rectal Bleeding.  // Tufts University Health & Nutrition Letter;Dec2001, Vol. 19 Issue 10, p4 

    Reports a case study of a patient suffering from a colorectal cancer in the U.S. Symptoms of the disease; Importance of blood test in patients with colorectal cancer; Causes of rectal bleeding.

  • Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. Ličar, Alenka; Cerkovnik, Petra; Novaković, Srdjan // Medical Oncology;Dec2011, Vol. 28 Issue 4, p1048 

    Numerous clinical studies have shown that anti-EGFR therapies are effective only in a subset of patients with colorectal cancer. Even though mutations in the KRAS gene have been confirmed as negative predictors of the response to EGFR-targeted therapies, not all KRAS wild-type (wt- KRAS)...

  • Clear cell adenocarcinoma of the colon is a unique morphological variant of intestinal carcinoma: Case report with molecular analysis. Barisella, Marta; Lampis, Andrea; Perrone, Federica; Carbone, Antonino // World Journal of Gastroenterology;11/14/2008, Vol. 14 Issue 42, p6575 

    Here we report a new case of clear cell adenocarcinoma (CCA) of the colon in a 54-year-old Caucasian man. Despite of the previous reported cases, the lesion was located in the right colon and was not associated with the conventional adenoma. We performed immunohistochemical and molecular...

  • Noninvasive Colon Check. Kozak, Diane; Harrar, Sari // Prevention;Jun2001, Vol. 53 Issue 6, p177 

    Reports on the development of a colon cancer test which measures abnormal DNA in cells found in stool samples.

  • Delay in Seeking Advice for Symptoms that Potentially Indicate Bowel Cancer. Cockburn, Jill; Paul, Chris; Tzelepis, Flora; McElduff, Patrick; Byles, Julie // American Journal of Health Behavior;Jul/Aug2003, Vol. 27 Issue 4, p401 

    Objectives: To document knowledge, behavior and experiences of adults regarding potential signs and symptoms of bowel cancer. Methods: Telephone interviews with 1332 randomly selected adults, using similar questions to a survey conducted in 1988. Results: Twenty three percent (n=306) of...

  • Evaluation of the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care population. Wilson, Sue; Wakelam, Michael J. O.; Hobbs, Richard F. D.; Ryan, Angela V.; Dunn, Janet A.; Redman, Val D.; Patrick, Fiona; Colbourne, Lynne; Martin, Ashley; Ismail, Tariq // BMC Cancer;2006, Vol. 6, p258 

    Background: Bowel cancer is common and is a major cause of death. Meta-analysis of randomised controlled trials estimates that screening for colorectal cancer using faecal occult blood (FOB) test reduces mortality from colorectal cancer by 16%. However, FOB testing has a low positive predictive...

  • Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study. Faivre, J; Tazi, M A; ElMrini, T; Lejeune, C; Benhamiche, A M; Dassonville, F // British Journal of Cancer;2/1/99, Vol. 79 Issue 3/4, p680 

    To estimate the efficacy of screening on colorectal cancer mortality, a population-based case-control study was conducted in well-defined areas of Burgundy (France). Screening by faecal occult blood test prior to diagnosis in cases born between 1914 and 1943 and who died of colorectal cancer...

  • Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study. Faivre, J; Tazi, M A; ElMrini, T; Lejeune, C; Benhamiche, A M; Dassonville, F // British Journal of Cancer;2/1/99, Vol. 79 Issue 3/4, p680 

    To estimate the efficacy of screening on colorectal cancer mortality, a population-based case-control study was conducted in well-defined areas of Burgundy (France). Screening by faecal occult blood test prior to diagnosis in cases born between 1914 and 1943 and who died of colorectal cancer...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics